特一藥業(002728.SZ):子公司藥品替硝唑片通過一致性評價
格隆匯12月3日丨特一藥業(002728.SZ)公佈,公司的全資子公司海南海力製藥有限公司(簡稱“海力製藥”)於近日獲得國家藥品監督管理局核准簽發的“替硝唑片”的《藥品補充申請批准通知書》,經審查,上述藥品通過仿製藥質量和療效一致性評價。
替硝唑片是一種抗原蟲藥和抗菌藥。用於治療滴蟲病、賈第鞭毛蟲病、阿米巴病、細菌性陰道炎、十二指腸潰瘍;用於治療各種厭氧菌感染,如:腹腔內感染、婦科感染、敗血症、術後傷口感染、皮膚軟組織感染、肺炎、肺部膿腫、胸腔積膿及急性潰瘍性牙齦炎;也可用於預防由厭氧菌引起的術後感染,如結腸、胃腸道和泌尿生殖系統手術後感染。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.